TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jul 18

PMID 35844550

Authors

Xiaohang Liu

Wei Wu

Ligang Fang

Yingxian Liu

Wei Chen

Affiliations

Soon will be listed here.

Abstract

With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors (ICIs) have become the main drugs used to treat many advanced malignant tumors. However, immune-related adverse events (irAEs), which might involve multiple organ disorders, should not be ignored. ICI-induced myocarditis is an uncommon but life-threatening irAE. Glucocorticoids are the first choice of treatment for patients with ICI-induced myocarditis, but high proportions of steroid-refractory and steroid-resistant cases persist. According to present guidelines, tumor necrosis factor alpha (TNF-α) inhibitors are recommended for patients who fail to respond to steroid therapy and suffer from severe cardiac toxicity, although evidence-based studies are lacking. On the other hand, TNF-α inhibitors are contraindicated in patients with moderate-to-severe heart failure. This review summarizes real-world data from TNF-α inhibitors and other biologic agents for ICI-induced myocarditis to provide more evidence of the efficacy and safety of TNF-α inhibitors and other biologic agents.

Citing Articles

Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action.

Malvaso A, Giglio P, Diamanti L, Gastaldi M, Vegezzi E, Pace A Brain Sci. 2024; 14(8).

PMID: 39199458 PMC: 11352216. DOI: 10.3390/brainsci14080764.

Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review.

Ma X, Chen J, Chen S, Lan X, Wei Z, Gao H Medicine (Baltimore). 2024; 103(30):e38991.

PMID: 39058879 PMC: 11272340. DOI: 10.1097/MD.0000000000038991.

Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity.

Hu X, Bukhari S, Tymm C, Adam K, Lerrer S, Henick B J Immunother Cancer. 2024; 12(3).

PMID: 38519059 PMC: 10961528. DOI: 10.1136/jitc-2023-008482.

Innate and adaptive immunity in acute myocarditis.

Golino M, Harding D, Del Buono M, Fanti S, Mohiddin S, Toldo S Int J Cardiol. 2024; 404:131901.

PMID: 38403204 PMC: 11450758. DOI: 10.1016/j.ijcard.2024.131901.

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.

Shalata W, Steckbeck R, Abu Salman A, Abu Saleh O, Abu Jama A, Attal Z Medicina (Kaunas). 2024; 60(2).

PMID: 38399513 PMC: 10890382. DOI: 10.3390/medicina60020224.

References

Johnson D, Balko J, Compton M, Chalkias S, Gorham J, Xu Y . Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016; 375(18):1749-1755. PMC: 5247797. DOI: 10.1056/NEJMoa1609214. View

Hunter C, Jones S . IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015; 16(5):448-57. DOI: 10.1038/ni.3153. View

Zhang W, Huang Q, Xiao W, Zhao Y, Pi J, Xu H . Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis. Front Immunol. 2020; 11:18. PMC: 7003246. DOI: 10.3389/fimmu.2020.00018. View

Fragoulis G, McInnes I, Siebert S . JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019; 58(Suppl 1):i43-i54. PMC: 6390879. DOI: 10.1093/rheumatology/key276. View

Mahmood S, Fradley M, Cohen J, Nohria A, Reynolds K, Heinzerling L . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16):1755-1764. PMC: 6196725. DOI: 10.1016/j.jacc.2018.02.037. View

Madhusudan S, Foster M, Muthuramalingam S, Braybrooke J, Wilner S, Kaur K . A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10(19):6528-34. DOI: 10.1158/1078-0432.CCR-04-0730. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

Jespersen M, Fano S, Stenor C, Moller A . A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. Eur Heart J Case Rep. 2021; 5(11):ytab342. PMC: 8637790. DOI: 10.1093/ehjcr/ytab342. View

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

10.

Bermas B, Zaha V . Mending Broken Hearts: A New Treatment Paradigm for Immune Checkpoint Inhibitor-Induced Myocarditis. Circulation. 2021; 143(8):767-769. DOI: 10.1161/CIRCULATIONAHA.120.052307. View

11.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

12.

Shah M, Tayar J, Abdel-Wahab N, Suarez-Almazor M . Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum. 2018; 48(4):736-740. DOI: 10.1016/j.semarthrit.2018.05.006. View

13.

Ruiz-Camps I, Aguilar-Company J . Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther Adv Infect Dis. 2021; 8:2049936121989548. PMC: 7897815. DOI: 10.1177/2049936121989548. View

14.

Gallegos C, Rottmann D, Nguyen V, Baldassarre L . Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J Case Rep. 2019; 3(1):yty149. PMC: 6439394. DOI: 10.1093/ehjcr/yty149. View

15.

Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D . Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992; 175(2):323-9. PMC: 2119112. DOI: 10.1084/jem.175.2.323. View

16.

Wallach D . Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol. 1984; 132(5):2464-9. View

17.

de Wilt J, Manusama E, van Tiel S, van Ijken M, Ten Hagen T, Eggermont A . Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 1999; 80(1-2):161-6. PMC: 2362986. DOI: 10.1038/sj.bjc.6690335. View

18.

Agrawal N, Khunger A, Vachhani P, Colvin T, Hattoum A, Spangenthal E . Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Rep Oncol. 2019; 12(1):260-276. PMC: 6465686. DOI: 10.1159/000498985. View

19.

Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H . Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 2017; 108(10):1947-1952. PMC: 5623748. DOI: 10.1111/cas.13332. View

20.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View